Wound Care: Tissue-Engineered Skin Replacements and Active Wound Repair Modulators
Wound Care: Tissue-Engineered Skin Replacements and Active Wound Repair Modulators
$4,750.00
This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the US, 5EU, Japan, and RoW markets for tissue-engineered skin replacements (epidermal, dermal, and multilayer equivalents, and amniotic tissue grafts) and active wound repair modulators (growth factors, gene therapy agents, and stem cells).
Publisher: Meddevicetracker
- Highlights
- Description
- Contents
Highlights
- In 2019, global sales of tissue-engineered skin replacements and wound modulators totaled more than $1.3bn; of this, tissue-engineered skin replacements accounted for more than 90% of sales. Over the forecast period covered by this report, total sales are expected to increase at a CAGR of 7.0%, reaching nearly $1.9bn in 2024.
- Drivers of the tissue-engineered wound care products market include the aging of the population and the increasing prevalence of obesity and diabetes, with an associated increase in the incidence of chronic, non-healing wounds that are resistant to traditional treatments.
- The COVID-19 pandemic puts a unique strain on the medtech market as a whole, as the number of elective and deferrable procedures experienced a rapid decrease in the first quarter of 2020, and into the second quarter. As the treatment of chronic wounds can only be deferred for a short time to avoid adverse outcomes for the patient, this market is expected to rebound more quickly than markets with a high volume of purely elective procedures.
Key topics covered
- A discussion of current/forecast markets, competitors, and opportunities in the global tissue-engineered skin replacements and wound modulators market, including dermal, epidermal, and multilayer equivalents; amniotic tissue grafts; and growth factor-based wound modulators
- related product portfolios offered by leading manufacturers
OVERVIEW
In 2019, sales of tissue-engineered skin replacements and wound modulators in the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World markets, totaled more than $1.3bn; of this, tissue-engineered skin replacements accounted for more than 90% of sales, with wound modulators accounting for the remaining sales. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for dermal, epidermal, and multilayer equivalents; amniotic tissue grafts; and growth factor-based wound modulators. Drivers of this market include the aging of the population and the increasing prevalence of obesity and diabetes, with an associated increase in the incidence of chronic, non-healing wounds that are resistant to traditional treatments. The COVID-19 pandemic puts a unique strain on the medtech market as a whole, as the number of elective and deferrable procedures experienced a rapid decrease in the first quarter of 2020, and into the second quarter. As the treatment of chronic wounds can only be deferred for a short time to avoid adverse outcomes for the patient, this market is expected to rebound more quickly than markets with a high volume of purely elective procedures. Over the forecast period covered by this report, total sales are expected to increase at a CAGR of 7.0%, reaching nearly $1.9bn in 2024.
CONTENTS
Executive Summary …………………………………………………………………….. ES-1
i. Tissue-engineered skin replacements………………………………………………………………… ES-1
ii. Wound modulators ……………………………………………………………………………………….. ES-3
iii. Market analysis ……………………………………………………………………………………………. ES-4
iv. Major competitors………………………………………………………………………………………… ES-6
v. Methodology………………………………………………………………………………………………… ES-6
Exhibit ES-1: Tissue-engineered skin replacements and wound modulators, market forecast ($m), 2019–24 ………………………………………………………………… ES-5
1. Tissue-Engineered Skin Replacements …………………………………………..1-1
1.1 Allografts………………………………………………………………………………………………………1-1
1.2 Autografts…………………………………………………………………………………………………….1-2
1.3 Xenografts…………………………………………………………………………………………………….1-3
1.4 Autologous and tissue-engineered skin replacements ………………………………………….1-3
1.4.1 Epidermal equivalent products …………………………………………………………..1-4
1.4.2 Dermal equivalent products……………………………………………………………….1-6
1.4.3 Multilayer equivalent products …………………………………………………………..1-8
1.4.4 Amniotic tissue grafts ……………………………………………………………………..1-10
1.5 Market forecast……………………………………………………………………………………………1-11
1.6 Competitive analysis……………………………………………………………………………………..1-16
1.6.1 Allergan/AbbVie……………………………………………………………………………..1-16
1.6.2 MiMedx Group ………………………………………………………………………………1-17
1.6.3 Organogenesis……………………………………………………………………………….1-18
1.6.4 Smith & Nephew…………………………………………………………………………….1-19
1.6.5 Wright Medical Technology ……………………………………………………………..1-21
1.6.6 Integra LifeSciences ………………………………………………………………………..1-22
1.6.7 Other suppliers………………………………………………………………………………1-23
1.7 Bibliography………………………………………………………………………………………………..1-25
Exhibit 1-1: Tissue-engineered skin replacements, market forecast, 2019–24………………1-15
Exhibit 1-2: Allergan, revenues by segment, FY2019………………………………………………..1-17
Exhibit 1-3: MiMedx Group, revenues, FY2019……………………………………………………….1-18
Exhibit 1-4: Organogenesis, revenues by segment, FY2019……………………………………….1-19
Exhibit 1-5: Smith & Nephew, revenues by segment, FY2019 ……………………………………1-20
Exhibit 1-6: Wright Medical Technology, revenues by segment, FY2019 ……………………..1-22
Exhibit 1-7: Integra LifeSciences, revenues by segment, FY2019 ………………………………..1-23
Exhibit 1-8: Tissue-engineered skin replacements market, share by supplier, 2019 ………1-24
2. Wound Modulators……………………………………………………………………2-1
2.1 Growth factors………………………………………………………………………………………………2-1
2.1.1 Growth factor classification………………………………………………………………..2-3
2.1.2 Competitors and products …………………………………………………………………2-9
2.1.3 Market forecast ……………………………………………………………………………..2-10
2.2 Gene therapy agents…………………………………………………………………………………….2-13
2.3 Stem cells……………………………………………………………………………………………………2-14
2.3.1 Types of stem cells………………………………………………………………………….2-14
2.3.2 The role of stem cells in wound healing………………………………………………2-18
2.4 Other active wound repair modulators and pharmaceuticals……………………………….2-19
2.4.1 Antibiotics and anti-infectives…………………………………………………………..2-19
2.4.2 Hormones……………………………………………………………………………………..2-20
2.4.3 Matrix metalloproteinase (MMP) enzyme inhibitors …………………………….2-20
2.4.4 Neuropeptides……………………………………………………………………………….2-21
2.4.5 Other products ………………………………………………………………………………2-22
2.5 Bibliography………………………………………………………………………………………………..2-23
Exhibit 2-1: Selected growth factors under development for wound healing applications………………………………………………………………………..2-4
Exhibit 2-2: Growth factors, market forecast ($m), 2019–24 …………………………………….2-12
Appendix: Company Listing……………………………………………………………. A-1
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Molecular Diagnostics Market 
Sign up to the